Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-10-17
2006-10-17
Ulm, John (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S069600, C435S252300, C530S388220, C536S023530
Reexamination Certificate
active
07122185
ABSTRACT:
The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg4:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
REFERENCES:
patent: 5994515 (1999-11-01), Hoxie
patent: 6107019 (2000-08-01), Allaway et al.
patent: 6265184 (2001-07-01), Gray et al.
patent: 6268477 (2001-07-01), Gray et al.
patent: 6344545 (2002-02-01), Allaway et al.
patent: 6448375 (2002-09-01), Samsom et al.
patent: 6511826 (2003-01-01), Li et al.
patent: 6528625 (2003-03-01), Wu et al.
patent: 6548636 (2003-04-01), Dragic et al.
patent: 6692938 (2004-02-01), Samsom et al.
patent: 6743594 (2004-06-01), Li et al.
patent: 6759519 (2004-07-01), Li et al.
patent: 6797811 (2004-09-01), Gray et al.
patent: 6025154 (2004-10-01), Li et al.
patent: 6800447 (2004-10-01), Samsom et al.
patent: 6800729 (2004-10-01), Li et al.
patent: 2001/0000241 (2001-04-01), Li et al.
patent: 2002/0048786 (2002-04-01), Rosen et al.
patent: 2002/0061834 (2002-05-01), Rosen et al.
patent: 2002/0076745 (2002-06-01), Li et al.
patent: 2002/0099176 (2002-07-01), Li et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2002/0106742 (2002-08-01), Samson et al.
patent: 2002/0110805 (2002-08-01), Samson et al.
patent: 2002/0110870 (2002-08-01), Samson et al.
patent: 2002/0132269 (2002-09-01), Li et al.
patent: 2002/0146415 (2002-10-01), Olson et al.
patent: 2002/0150888 (2002-10-01), Gray et al.
patent: 2003/0023044 (2003-01-01), Li et al.
patent: 2003/0044411 (2003-03-01), Olson et al.
patent: 2003/0092632 (2003-05-01), Dragic et al.
patent: 2003/0100058 (2003-05-01), Roschke et al.
patent: 2003/0166024 (2003-09-01), Rosen et al.
patent: 2004/1110127 (2004-06-01), Samsom et al.
patent: 2004/0151719 (2004-08-01), Li et al.
patent: 2004/0161739 (2004-08-01), Samsom et al.
patent: 2004/0230037 (2004-11-01), Gray et al.
patent: 2005/0154193 (2005-07-01), Roschke et al.
patent: 19972216990 (1997-11-01), None
patent: 9687000211 (1996-03-01), None
patent: 968701029 (1996-08-01), None
patent: 0815137 (1998-11-01), None
patent: 0883687 (1998-12-01), None
patent: 1145721 (2001-10-01), None
patent: 1146055 (2001-10-01), None
patent: 1146122 (2001-10-01), None
patent: 1148126 (2001-10-01), None
patent: 1148127 (2001-10-01), None
patent: 1149582 (2001-10-01), None
patent: 1199360 (2002-04-01), None
patent: 1482042 (2004-12-01), None
patent: WO 9639437 (1996-12-01), None
patent: WO 722698 (1997-06-01), None
patent: 9726009 (1997-07-01), None
patent: WO 97032019 (1997-09-01), None
patent: 9641020 (1997-10-01), None
patent: 9737005 (1997-10-01), None
patent: WO 9744055 (1997-11-01), None
patent: 9749424 (1997-12-01), None
patent: WO/9745543 (1997-12-01), None
patent: WO/9747318 (1997-12-01), None
patent: 9747319 (1998-01-01), None
patent: WO9818826 (1998-05-01), None
patent: 9856421 (1998-12-01), None
patent: 0035409 (2000-06-01), None
patent: WO 0158915 (2001-08-01), None
patent: WO 0158916 (2001-08-01), None
patent: 0164710 (2001-09-01), None
patent: 0222077 (2002-03-01), None
patent: WO 02064612 (2002-08-01), None
patent: 02068608 (2002-09-01), None
patent: 02083172 (2002-10-01), None
patent: 03072766 (2003-09-01), None
Allaway, G.P., K.L. Davis-Bruno, B.A. Beaudry, E.B. Garcia, E.L. Wong, A.M. Ryder, K.W. Hasel, M.C. Gaudin, R.A. Koup, J.S. McDougal and P.J. Maddon. 1995 Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 11:533-539.
Allaway, G.P., A.M. Ryder, G.A. Beaudry and P.J. Maddon 1993. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res. Hum. Retroviruses 9:581-587.
Amara, A., S.L. Gall, O. Schwartz, J. Salamero, M. Montes, P. Loetscher, M. Baggiolini, J.L. Virelizier and F. Arenzana-Seisdedos. 1997. HIV coreceptor downregulation as antiviral principle: SDF-la-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 186:139-146.
Berger, E.A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11 (suppl A): S3-S16.
Bieniasz, P.D., R.A. Fridell, I. Aramori, S.S.G. Ferguson, M.C. Caron and B.R. Cullen. 1997. HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR5 co-receptor. EMBO 16:2599-2609.
Brelot, A., N. Heveker, O. Pleskoff, N. Sol and M. Alizon. 1997. Role of the first and third extracellular domains of CXCR4 in human immunodeficiency virus coreceptor activity. J. Virol. 71:4744-4751.
Chan, D.C. and P.S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
Connor, R.I. K.E. Sheridan, D. Ceradini, S. Choe and N.R. Landau. 1997. Change in co-receptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 185:621-628.
Crump, M.P., J.H. Gong, P. Loetscher, K. Rajarathnam, A. Amara, R. Arenzana-Seisdedos, J.L. Virelizier, M. Baggiolini, B.D. Sykes and I. Clark-Lewis. 1997. Solution structure and basis for functional activity of stromal-cell derived factor-1; disassociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO 16:6996-7007.
Dalgleish, A.G., P.C.L. Beverly, P.R. Clapham, D.H. Crawford, M.F. Greaves and R.A. Weiss 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus Nature 312:763-766.
Donzella, G.A., D. Schols, S.W. Lin, J.A. Este, K.A. Nagashima, P.J. Maddon, G.P. Allaway, T.P. Sakamar, G. Henson, E.D. Clercq and J.P. Moore. 1998 AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:72-77.
Doranz, B.J., K. Grovit-Ferbas, M.P. Sharron, S.H. Mao, M.B. Goetz, E.S. Daar, R.W. Doms and W.A. O'Brien. 1997. A small molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 co-receptor. J. Ex. Med. 186:1395-1400.
Doranz, B.J., Z-H. Lu, J. Rucker, T.-Y Zhang M. Sharron, Y.-H Cen, Z.-X. Wang, H.-H Guo, J.-G Du, M.A. Accavitti, R.W. Doms and S.C. Peiper. 1997. Two distinct CCR5 domains can mediate co-receptor usage by human immunodeficiency virus type 1. J. Virol. 71:6305-6314.
Dragic, T., V. Litwin, G.P. Allaway, S.R. Martin, Y. Huanh, K.A. Nagashima, C. Cayanan, P.J. Maddon, R.A. Koup, J.P. Moore and W.A. Moore and W.A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
Hill, C.M., D. Kwon, M. Jones, C.B. Davis, S. Marmon, B.L. Daugherty, J.A. DeMartino, M.S. Springer, D. Unutmaz and D.R. Littman. 1998. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 248:257-371.
Kwong, P.D., R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski and W.A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
Laal, S., S. Burda, M.K. Gorny, S. Karwowska, A. Buchbinder and S. Zolla-Pazner. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations f human monoclonal antibodies. J. Virol. 68:4001-4008.
Li, A., H. Katinger, M.R. Posner, L. Cavacini, S. Zolla-Pazner, M.K. Gorny, J. Sodroski, T.C. Chou, T.W. Baba and R.M. Ruprecht. 1998. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+by triple and quadruple combinations of human monoclonal antibodies and hig-titer antihuman immunodeficiency virus type 1 immunoglobulins. J. Virol. 72:3235-3240.
Mack, M., B. Luckow, P.J. Nelson, J. Cihak, G. Simmons, P.R. Clapham, N. Signoret, M. Marsh, M. Stangassinger, F. Borlat, T.N.C. Wells, D. Schlondorff and A.E.I. Proudfoot. 1998. Aminooxypentane-RANTES induces CCR5 internalization
Hinton Paul R.
Maddon Paul J.
Olson William C.
Tsurushita Naoya
Vasquez Maximillano
Cooper & Dunham LLP
PDL Biopharma, Inc.
Progenics Pharmaceuticals Inc.
Ulm John
White, Esq. John P.
LandOfFree
Anti-CCR5 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CCR5 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CCR5 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3698685